Leiden, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans Schikan, Chief Executive Officer, will present a corporate overview at the NewsMakers in the Biotech Industry Conference on Friday, September 26 at 9:00am EDT and participate in a fireside chat at the Leerink Partners Rare Disease Roundtable at 1:05pm EDT in New York, NY. Live webcasts of the presentations can be accessed through the Investors & Media section of the Prosensa corporate website at www.prosensa.com and will be archived for 90 days.
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), Myotonic dystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com